OR WAIT null SECS
2,500+ International Professionals from Industry, Academia, and Regulatory Agencies Convene in Paris: 17 Meeting Tracks Including 400+ Speakers, 170+ Exhibits and 14 Tutorials
PARIS – The Drug Information Agency (DIA) kicked off its 18th Annual EuroMeeting at Le Palais des Congres with record-breaking attendance. An international, neutral forum for the exchange of multi-disciplinary drug information, the conference will address the latest developments in important European initiatives, including paediatrics, advanced therapies, the technology platform, pharmacogenomics, pharmacovigilance and risk management planning.
"With a bold agenda, including sessions on the revised Pharmaceutical Legislation, the 18th Annual DIA EuroMeeting is a 'not to miss' event," said David Maola, executive director of DIA. "The meeting will address a multitude of issues that will help improve the lives of people around the world."
The 18th Annual EuroMeeting will feature over 170 exhibits and 400 speakers presenting on topics organised into 17 session tracks:
In addition to 14 tutorials led by a variety of skilled professionals, keynote speakers Georgette Lalis, European Commission, DG Enterprise and Industry, and Jean-Francois Dehecq, sanofi-aventis, will be featured at the event.
On the evening of Tuesday, March 7, there will be a French Agency Satellite Meeting on "The Involvement of France in The European Networks for Evaluation and Monitoring of Health Products," featuring an opening and plenary by Jean Marimbert, General Director of Afssaps, France, followed by a Round Table Discussion on the Common Vision on Clinical Trials in France with Representatives of LEEM, INSERM, Afssaps and French hospital networks.
For more information on DIA's 18th Annual EuroMeeting, please download the programme at http://www.diahome.org/Content/Events/06101.pdf.
About the Drug Information Association (DIA)
The Drug Information Association serves more than 23,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, Pa., USA, and with offices in Basel, Switzerland and Tokyo, Japan, the association is led by its volunteer-based board of directors and executive management team. For more information, visit www.diahome.org, call +1.215.442.6100, or in Europe +22.214.171.12451.